The BIOIATRIKI Group, a leader in Primary Healthcare, announces the successful legal completion of its acquisition of Pavlidis Laboratories. This strategic move strengthens the Group's presence across Cyprus, especially in the Limassol and Paphos regions, aiming to further expand its high-level primary healthcare services to all patients.

With the incorporation of Pavlidis Laboratories into the BIOIATRIKI Group, patients visiting these laboratories will have access to over 3,500 clinical laboratory tests.

In addition, the branches are set to undergo gradual renovation within 2024, aiming to optimize patient experience and service.

Mr. Georgios Spanos, President of the BIOIATRIKI Group, stated, “The strategic investment in the acquisition of Pavlidis Laboratories is a significant step in our company's development and further strengthens our presence in Cyprus. By joining forces with Pavlidis Laboratories, we reaffirm our commitment to delivering even greater value to our patients and continue to innovate, grow, and lead developments in our sector!”

Mr. Anastasios Kalogiannis, Director of Operations and Development of the BIOIATRIKI Group in Cyprus, commented, “We are thrilled and proud to announce the successful completion of the absorption process of Pavlidis Laboratories by the BIOIATRIKI Group in Cyprus. This strategic move significantly enhances our presence in the Limassol and Paphos regions, offering residents comprehensive, high-level services, and the opportunity to utilize the full range of clinical laboratory tests available through our Group in Greece and Cyprus. With our services becoming increasingly accessible to all, without geographical, economic, or other limitations, and always adhering to our well-known triptych of development ‘Quality – Reliability – Innovation,’ we renew our promise to continue investing in and supporting Health in the Republic of Cyprus.”

Dr. Stefanos Pavlidis, (Biomedical Scientist), thanked the BIOIATRIKI Group for their trust and choice, emphasizing that the absorption of Pavlidis Laboratories into the BIOIATRIKI Group, a leading private provider of primary healthcare services in Greece and Cyprus, enables the absorbed centers to significantly and substantially upgrade their services to the residents of Limassol and Paphos, expanding their diagnostic capacity and reliability while also enhancing their quality footprint.

Since 2017, the BIOIATRIKI Group has been active in Cyprus, establishing, staffing, and operating the clinical laboratory of the German Oncology Center, and also acquiring the majority stake in Giannoukas Laboratories and ALFA EURESIS Diagnostic Center. With the addition of Pavlidis Laboratories, the BIOIATRIKI Group now boasts in Cyprus 2 accredited clinical laboratories, a radiology center with 2 fully equipped branches and various machines per examination category, 25 sampling centers, and the first Multi-Diagnostic Center in Nicosia, equipped with the most modern Clinical Laboratory and Radiodiagnostic equipment, including widespread automation, multiple innovations with artificial intelligence, radiation reduction software, and specialized scientific and medical staff.